| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2271a966935737b6416b7614859d303 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-409 |
| filingDate |
2020-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae720ae4e6968589e56b60774a0d7c56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff5cf5985d4db8dfb4f2e476e1cdd2f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20dd0006a7c64a1bfe5d3c5d2522b1fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88d04f17a4acc77a88f86125895136cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdf82b23122b814d37dd19e441f01cb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0815ecfe10ad6d4a13ce0af0039d192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9572949d0326bb40817217b82300ccc |
| publicationDate |
2021-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202135805-A |
| titleOfInvention |
Pharmaceutical compositon for preventing or treating fibrosis, containing pheophorbide compound as active ingredient |
| abstract |
The present invention relates to a pharmaceutical composition for preventing or treating fibrosis, containing a pheophorbide compound as an active ingredient. The pharmaceutical composition can effectively inhibit fibrosis of tissues by inhibiting signaling of TGF-[beta] which causes fibrosis and inhibiting activation and expression of collagen and fibronectin, and is significantly superior in the anti-fibrotic activity compared to nintedanib or pirfenidone, which are commercially available therapeutic agents for pulmonary fibrosis, and therefore may be widely used in the prevention or treatment of fibrosis. |
| priorityDate |
2019-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |